• Home
  • About Us
  • Become an Investor

Become an Investor



"I am a founding investor in Ace Vision and I am honored to be part of a company that is developing such an innovative and minimally invasive therapy to treat the loss of vision that occurs with aging. I invested in Ace Vision immediately after receiving the LaserACE® procedure myself when I was 47 years old. I was able to read a menu within one hour after having the surgery and after over 10 years have passed I am still enjoying the effects that this procedure has had on my quality of life. This kind of technology is urgently needed with the ever growing aging population and will have a huge impact on the industry of ophthalmology."

Robert M. Picerne
Board of Director, Ace Vision Group, Inc.
Founder & Managing Director Picerne Group

Additional Investor Testimonials


"I have been an angel investor, portfolio manager and VC for over 35 years specializing in medical procedures, devices and drugs; as well as being part of the start up of five oil and gas E&P companies. I have had the pleasure of being part of Ace Vision’s ascension from concept to reality since late 2012. During that time, the company has made monumental strides in perfecting the process to bring Ace Vision to the masses. It is very close to being ready for prime time. From an investor’s perspective, this procedure has it all. First, one of the largest addressable and willing markets of any I have ever seen. Second, AVG enjoys a very receptive distribution channel (ophthalmic surgeons) that is craving a safe simple complimentary procedure to LASIK. Ace Vision is just such a procedure. It is a natural fit for those who had LASIK years ago for distance, and now are finding their close-up vision becoming increasingly problematic. Ace Vision is indeed a safe, simple, effective [and lucrative] solution for both the surgeon and the patient to this ubiquitous symptom of the aging population, myself being one of them. Finally, AVG has a founder and innovator that has more passion, energy and aptitude for this project than any CEO I have ever worked with in any industry. She routinely runs the operation in a Spartan manner according to a well articulated path to exit. She get’s more results with less capital than can be expected, and delivers on milestones with almost clockwork precision. In my opinion, with proper funding, this team and procedure WILL succeed beyond anyone’s imagination."

Jay F. Joliat
CEO/CIO Joliat Ventures, LLC


"I have been in the ophthalmic industry for over 35 years and have had many roles including sales and marketing, FDA and CE mark approvals of several ophthalmic device technologies, and also raised capital for various start up technologies which were acquired for multi-million dollars

Surgical treatment of presbyopia is one the biggest market opportunities in ophthalmology, maybe in all of medicine – 100% of the population will have to deal with degradation of near vision as they age. The market opportunity is multi-billion dollar. Several surgical technologies are currently available, and more are in development - all with limitations.

The LaserACE® procedure has a unique safety profile that will make it perhaps the most attractive to both surgeons and patients. The effectiveness will allow most patients the opportunity to live without need for reading glasses, no negative risk on quality of vision, and most impactful will offer these benefits while making overall eye health improve! This is the unique opportunity with LaserACE® – improved near vision and improved eye health. I am very excited to be part of assisting this technology in its development and delivery to the commercial global market. "

Jim Simms
Global Director of Sales & Marketing


"I have been an Entrepreneur & CEO or over 40+ years of major corporations such as Paragon Trade Brands. I also serve on multiple boards of start- up and innovative companies. I joined Ace Vision Group’s Board in 2006 at an early stage when the LaserACE® procedure was being developed to restore the natural zooming capacity of the eye to focus on near and far distances without the aid of bifocals or progressive lenses. on the early clinical data showed good evidence that the procedure was safe and worked -including Bob Picerne, a patient turned major Angel Funder after having it performed on his own eyes.

Ace Vision has current objectives to expand the testing and validate the safety and reliability of results followed by regulatory approvals and claims in Taiwan, China and eventually USA. Their strategic plan includes developing tools and materials for practicing the procedure so it could be safely and reliably be practiced commercially by licensed and trained ophthalmologists anywhere in the world.

ACE Vision will change the way active people over 50 – the largest growing segment of global populations – will accommodate to presbyopia. Dr. AnnMarie Hipsley, Founder & CEO, has assembled an extra-ordinary group of experts and technology partners to progress the tools and clinical studies and be ready for commercial launch in the next 2 to 4 years. Her vision, creativity and tenacity is just what is needed to succeed in this extraordinary venture.

I have confidence that with adequate funding, ACE Vision will be as successful as Lasik or cataract surgery both as a boon to older people and to investors in the venture. "

Bobby Abraham


"We are always impressed with the service orientation we find when we interact with the Ace Vision Group team. As a part co-founders and very early investors of the company we find that the people listen carefully to advice and that they get the points very quickly. They respond to questions almost immediately and address problems very effectively. They are really easy to work with and they appreciate and value their angel investors. Ace Vision Group makes our portfolio investments a lot easier to monitor. We are very proud and honoured to be part of your innovative company."

Founder and Chairman of the Board of Astralis Corporation (U.S.A.)
Founder and Managing Director of Multibreen Beheer B.V. (The Netherlands)I


"I have been an entrepreneur and successful entrepreneur for over X years. I own multiple manufacturing and health care entities including a cosmetic surgery center and distribution for ophthalmic medical devices. We joined Ace Vision Group as a partner and distributor in 2006. Together we successfully obtained within two years both the Taiwan and FDA approval of the VisioLIte® laser. We have now in 2015 just completed together our first Taiwan clinical trial. We were so impressed with the results we invested in all that tranches originally committed to feeling confident of our ROI after seeing the results.

Our business experience with Ace Vision been excellent. We feel our partnership has been very effective and our relationship with the founder & CEO, Dr. AnnMarie Hipsley, has been held in high regard. We have been able to progress our business and clinical objectives with full support from Ace Vsiion. Our commitment to Ace Vision and our mutual success is demonstrated by our establishing a surgical suite and Taiwan headquarters for Ace Vision and the LaserACE® procedure. The most important ingredient in our relationship with Ace Vision is our total confidence in the integrity and transparency with which all of our business transactions have been met with. We are proud to be part of this innovative and much needed eye laser solution for the Asian market. "

Sam Chen
( King-Te Chen 陳金德)
Founder and Chairman of the BOD of Vision Renu, Taiwan Corporation
Founder and Chairman of the BOD of Grammy International Health
Founder &Chairman of the BOD of Young Wha Enterprise
Director of SunMax Biotech

The Ace Vision Opportunity

Presbyopia is one of a very few conditions that is universal across gender and ethnicity, impacting almost 90% of every single human being around the age of 40-45. There are over 1 billion people who suffer from presbyopia worldwide and this total is expected to reach 2.2 billion by the year 2020. Out of these, there are at least a half a billion who do not have access to reading glasses1. AVG’s technology has an impact not only on quality of life factors but also the socioeconomic burden of age-related vision loss.

The worldwide Market Opportunity is truly Massive and there is a totally UNMET need for therapeutic or surgical presbyopia treatment. AVG’s target market spans presbyopic pre-cataract patients generally age 40-60.   The potential market exceeds 100M patients in the US alone with approximately 4M new patients annually as the population ages2,  Treating a 5% share of just the US presbyopic population between 40–60 years of age (approximately 100 million people), creates a multi-billion dollar market opportunity.

China is not just the world's leading manufacturer of spectacles but is also the largest potential consumer of such products. Children and elderly people alike are consumers. Euromonitor International estimated that China's spectacles market grossed nearly Rmb56.7 billion with a 15% growth in 2013. Its market for contact lenses also grew by 14% to Rmb3.4 billion. In addition, according to data from China’s population census and statistical yearbooks, China is faced with the challenge of an aging population. During the 13 years from 2000 to 2012, the percentage of people aged 45 and above rose from 26.2% to 35% and the growth is expected to continue. Based on the experience that most middle-aged people begin to wear presbyopic glasses at the age of 42, the market potential is not to be underestimated.

AVG has established its LaserACE® brand in the core primary markets of Taiwan & China and has had partnerships in both countries for almost 8 years. AVG will leverage its relationships in Taiwan & China to build seed markets in Asia –its core target market for commercialization of its Gen II technology.

AVG has already established human clinical data in Taiwan, China, Mexico, Western Europe, South America and Canada with compelling results establishing early safety and general efficacy of procedure as a treatment of presbyopia. This preliminary data suggests that the LaserACE® treatment can potentially delay need for reading glasses by 5 to 10 years or potentially longer while patients experienced NO LOSS in pre-treatment distance vision.

AVG’s technology has a unique competitive advantage over other presbyopia solutions in that No other surgical procedure provides an increase in near vision without the “trade off” of negatively impacting some other aspect of vision. It is a truly disruptive technology paving a new genre of therapeutic refractive surgery that does not touch the visual optics of the eye. This unique feature to the LaserACE® procedure has created a large wave of excitement about the potential of this type of procedure in the ophthalmology surgeon audience as the podium presence of Ace vision has progressed with the long term study data. To see what doctors are saying about LaserACE® click here.

AVG has adopted the same well established economic model with LASIK as precedent of high-margin per-procedure fees in conjunction with purchase or lease of laser. This financial platform provides for a compelling ROI for doctors to drive adoption of this short duration, high volume procedure. LASIK has long ago achieved the acceptance in the market for laser eye surgery so this model is a low obstacle high ROI model for Ace Vision.

Ace Vision is the only company pursuing an laser eye therapy approach for treating presbyopia. Ace Vision is confident that clinical trials with the next generation automated (Gen II) system will continue to demonstrate the LaserACE® laser eye therapy is an ultra -minimally invasive safe treatment to address the presbyopia problem without affecting the eyes normal distance vision or utilizing artificial implants.

AVG has a clear exit strategy with multiple, high valuation comparable transactions. Ace Vision has raised approximately $6.5MM to date for its initial research development and early clinical trial work. Ace Vision is currently actively raising an $15MM private placement to continue its research development programs, clinical trial work, and to develop and manufacturer its Gen II technology platform for expanded clinical trials. To view our milestone progress to date click here.

1Global Vision Impairment Due to Uncorrected Presbyopia’, Archives of Ophthalmology, Vol 126 (No. 12), Dec 2008.
2US Census Data 2014.

Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.